Brentuximab for Newly Diagnosed Hodgkin Disease (NCT02398240)
The addition of brentuximab vedotin (Adcetris®; Seattle Genetics Inc./Takeda Oncology) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).
This trial is sponsored by Mitchell Cairo, New York Medical College. 
- Condition: Hodgkin Lymphoma
- Phase: II
- Estimated Enrollment: 40
- Start: May 2015
- Completion: June 2019
- Last verified: March 2015
Last Editorial review: July 17, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.